MGO One Seven LLC Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

MGO One Seven LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 35.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,788 shares of the medical research company’s stock after purchasing an additional 1,243 shares during the period. MGO One Seven LLC’s holdings in IQVIA were worth $1,012,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. 9258 Wealth Management LLC raised its holdings in IQVIA by 35.9% during the 4th quarter. 9258 Wealth Management LLC now owns 2,915 shares of the medical research company’s stock valued at $674,000 after acquiring an additional 770 shares during the period. QRG Capital Management Inc. raised its stake in shares of IQVIA by 14.1% during the 4th quarter. QRG Capital Management Inc. now owns 4,879 shares of the medical research company’s stock valued at $1,129,000 after purchasing an additional 603 shares during the period. Avantax Advisory Services Inc. lifted its holdings in IQVIA by 39.6% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,702 shares of the medical research company’s stock worth $625,000 after purchasing an additional 766 shares in the last quarter. Norges Bank bought a new position in IQVIA in the 4th quarter worth about $383,705,000. Finally, BI Asset Management Fondsmaeglerselskab A S increased its position in shares of IQVIA by 36.7% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 15,621 shares of the medical research company’s stock valued at $3,614,000 after buying an additional 4,195 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. UBS Group raised their price objective on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Truist Financial boosted their price target on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Thursday, September 5th. Robert W. Baird boosted their target price on IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 23rd. Finally, The Goldman Sachs Group started coverage on IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $266.67.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $238.70 on Friday. The stock has a market capitalization of $43.49 billion, a price-to-earnings ratio of 32.61, a price-to-earnings-growth ratio of 2.23 and a beta of 1.49. The company has a fifty day moving average of $237.98 and a 200-day moving average of $234.47. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the firm earned $2.22 earnings per share. Equities research analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.